A High-Affinity Fully Human Anti–IL-6 mAb, 1339, for the Treatment of Multiple Myeloma

2009116 citationsJournal Articlebronze Open Access

Authors

Mariateresa Fulciniti · VA Boston Healthcare System

Teru Hideshima · VA Boston Healthcare System

Claudine Vermot‐Desroches · Vaccinex (United States)

Samantha Pozzi · Dana-Farber Cancer Institute

Puru Nanjappa · Vaccinex (United States)

Zhenxin Shen · Vaccinex (United States)

Nipun Patel

Abstract

Our data confirm in vitro and in vivo anti-multiple myeloma activity of, as well as inhibition of bone turnover by, fully humanized mAb 1339, as a single agent and in combination with conventional and novel agents, providing a rationale for its clinical evaluation in multiple myeloma.

Topics & Keywords

Multiple Myeloma Research and Treatments Phytochemical compounds biological activities Monoclonal and Polyclonal Antibodies Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 15, Issue 23, pp. 7144-7152

DOI: 10.1158/1078-0432.ccr-09-1483

Field-Weighted Citation Impact: 5.20